A Phase 1/2 Open-Label, Dose Escalation Study Investigat

  • Ustun, Celalettin (PI)

Project: Research project

Project Details

Description

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
StatusFinished
Effective start/end date12/6/1312/30/18

Funding

  • Astellas Pharma US, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.